Literature DB >> 30853505

Lack of Antinociceptive Cross-Tolerance With Co-Administration of Morphine and Fentanyl Into the Periaqueductal Gray of Male Sprague-Dawley Rats.

Erin N Bobeck1, Shauna M Schoo2, Susan L Ingram3, Michael M Morgan2.   

Abstract

Tolerance to the antinociceptive effect of mu-opioid receptor agonists, such as morphine and fentanyl, greatly limits their effectiveness for long-term use to treat pain. Clinical studies have shown that combination therapy and opioid rotation can be used to enhance opioid-induced antinociception once tolerance has developed. The mechanism and brain regions involved in these processes are unknown. The purpose of this study was to evaluate the contribution of the ventrolateral periaqueductal gray (vlPAG) to antinociceptive tolerance and cross-tolerance between administration and co-administration of morphine and fentanyl. Tolerance was induced by pretreating rats with morphine or fentanyl or low-dose combination of morphine and fentanyl into the vlPAG followed by an assessment of the cross-tolerance to the other opioid. In addition, tolerance to the combined treatment was assessed. Cross-tolerance did not develop between repeated vlPAG microinjections of morphine and fentanyl. Likewise, there was no evidence of cross-tolerance from morphine or fentanyl to the co-administration of morphine and fentanyl. Co-administration did not cause cross-tolerance to fentanyl. Cross-tolerance was only evident to morphine or morphine and fentanyl combined in rats pretreated with co-administration of low doses of morphine and fentanyl. This finding is consistent with the functionally selective signaling that has been reported for antinociception and tolerance after morphine and fentanyl binding to the mu-opioid receptor. This research supports the notion that combination therapy and opioid rotation may be useful clinical practices to decrease opioid tolerance and other side effects. PERSPECTIVE: This preclinical study shows that there is a decrease in cross-tolerance between morphine and fentanyl within the periaqueductal gray, which is a key brain region in opioid antinociception and tolerance.
Copyright © 2019 the American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Opioid; analgesia; cross-tolerance; functional selectivity; mu-opioid receptor

Mesh:

Substances:

Year:  2019        PMID: 30853505      PMCID: PMC6732057          DOI: 10.1016/j.jpain.2019.03.002

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  47 in total

1.  Tolerance to the antinociceptive effect of morphine microinjections into the ventral but not lateral-dorsal periaqueductal gray of the rat.

Authors:  V Tortorici; C S Robbins; M M Morgan
Journal:  Behav Neurosci       Date:  1999-08       Impact factor: 1.912

2.  Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction.

Authors:  J L Whistler; H H Chuang; P Chu; L Y Jan; M von Zastrow
Journal:  Neuron       Date:  1999-08       Impact factor: 17.173

3.  The use of opioids in the postoperative setting: focus on morphine, hydromorphone, and fentanyl.

Authors:  Julie Golembiewski; Sherri Torrecer; Jennifer Katke
Journal:  J Perianesth Nurs       Date:  2005-04       Impact factor: 1.084

4.  Mu-opioid receptor down-regulation and tolerance are not equally dependent upon G-protein signaling.

Authors:  Benedict A Gomes; Ji Shen; Kristi Stafford; Minesh Patel; Byron C Yoburn
Journal:  Pharmacol Biochem Behav       Date:  2002-05       Impact factor: 3.533

5.  Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal.

Authors:  A K Finn; J L Whistler
Journal:  Neuron       Date:  2001-12-06       Impact factor: 17.173

6.  Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes.

Authors:  Elizabeth A Bolan; Ronald J Tallarida; Gavril W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

7.  Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats.

Authors:  F B Ross; S C Wallis; M T Smith
Journal:  Pain       Date:  2000-02       Impact factor: 6.961

8.  Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization, and endocytosis of mu-opioid receptors.

Authors:  Stephanie L Borgland; Mark Connor; Peregrine B Osborne; John B Furness; MacDonald J Christie
Journal:  J Biol Chem       Date:  2003-03-17       Impact factor: 5.157

9.  Distinct domains of the mu-opioid receptor control uncoupling and internalization.

Authors:  Jeremy Celver; Mei Xu; Wenzhen Jin; Janet Lowe; Charles Chavkin
Journal:  Mol Pharmacol       Date:  2004-03       Impact factor: 4.436

10.  Addition of a second opioid may improve opioid response in cancer pain: preliminary data.

Authors:  Sebastiano Mercadante; Patrizia Villari; Patrizia Ferrera; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2004-11       Impact factor: 3.603

View more
  7 in total

Review 1.  Unique Pharmacology, Brain Dysfunction, and Therapeutic Advancements for Fentanyl Misuse and Abuse.

Authors:  Ying Han; Lu Cao; Kai Yuan; Jie Shi; Wei Yan; Lin Lu
Journal:  Neurosci Bull       Date:  2022-05-15       Impact factor: 5.271

2.  Use of home cage wheel running to assess the behavioural effects of administering a mu/delta opioid receptor heterodimer antagonist for spontaneous morphine withdrawal in the rat.

Authors:  Michael M Morgan; Danielle L Peecher; John M Streicher
Journal:  Behav Brain Res       Date:  2020-10-06       Impact factor: 3.332

3.  Effects of dezocine on morphine tolerance and opioid receptor expression in a rat model of bone cancer pain.

Authors:  Lin-Xin Wu; Yan-Peng Dong; Qian-Mei Zhu; Bo Zhang; Bo-Lun Ai; Tao Yan; Guo-Hua Zhang; Li Sun
Journal:  BMC Cancer       Date:  2021-10-20       Impact factor: 4.430

4.  GPR171 activation regulates morphine tolerance but not withdrawal in a test-dependent manner in mice.

Authors:  Leela Afrose; Max V McDermott; Ashif I Bhuiyan; Sanjai K Pathak; Erin N Bobeck
Journal:  Behav Pharmacol       Date:  2022-08-05       Impact factor: 2.277

5.  Fentanyl depression of respiration: Comparison with heroin and morphine.

Authors:  Rob Hill; Rakulan Santhakumar; William Dewey; Eamonn Kelly; Graeme Henderson
Journal:  Br J Pharmacol       Date:  2019-12-23       Impact factor: 8.739

6.  Melatonin alleviates morphine analgesic tolerance in mice by decreasing NLRP3 inflammasome activation.

Authors:  Qianjin Liu; Ling-Yan Su; Chunli Sun; Lijin Jiao; Ying Miao; Min Xu; Rongcan Luo; Xin Zuo; Rongbin Zhou; Ping Zheng; Wei Xiong; Tian Xue; Yong-Gang Yao
Journal:  Redox Biol       Date:  2020-04-29       Impact factor: 11.799

Review 7.  Adrenomedullin: an important participant in neurological diseases.

Authors:  Feng-Jiao Li; Si-Ru Zheng; Dong-Mei Wang
Journal:  Neural Regen Res       Date:  2020-07       Impact factor: 5.135

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.